The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
TG Therapeutics' stock jumped 9.5% following positive Phase I data for the subcutaneous formulation of Briumvi. On the same day, Edgewise Therapeutics sold its muscular dystrophy program to Servier in a deal valued at $2.65 billion, receiving $1.55 billion in upfront cash to fund the development of EDG-7500 for hypertrophic cardiomyopathy. Phase 2 data for EDG-7500 is expected in Q2 2026. Additionally, UK-listed Oxford BioMedica rejected multiple unsolicited offers from EQT, stating that any takeover deal would need to align with its strategy.